Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Emerging Cancer Vaccines Market by Type (Non Genetic Vaccines, Genetic Vaccines), By Application (Cancer Research Centers, Cancer Hospital, Clinics, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Emerging Cancer Vaccines Market by Type (Non Genetic Vaccines, Genetic Vaccines), By Application (Cancer Research Centers, Cancer Hospital, Clinics, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 189527 3300 Pharma & Healthcare 377 233 Pages 4.7 (44)
                                          

The global emerging cancer vaccines market is expected to grow at a CAGR of 8.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of cancer and rising awareness about the benefits of vaccination against cancer. The non-genetic vaccines segment accounted for a major share in the global emerging cancer vaccines market in 2018, owing to their low cost and ease of production. However, genetic vaccines are expected to witness significant growth during the forecast period due to their ability to target specific types of cancers with high efficacy rates. Non-genetic vaccines accounted for a major share in the global emerging cancer vaccine market in 2018, owing to their low cost and ease of production. Genetic vaccines are expected to witness significant growth during the forecast period due to their ability against specific types of cancers with high efficacy rates. -The global cancer vaccine market is expected to grow at a CAGR of 12.5% from 2017 to 2022. -The global cancer vaccine market is expected to reach USD 3.2 billion by 2022. -Cancer vaccines are used for the prevention and treatment of various types of cancers such as breast cancer and prostate cancer. Cancer vaccines are also used for the prevention and treatment of various types of cancers such as breast cancer and prostate cancer.

Industry Growth Insights published a new data on “Emerging Cancer Vaccines Market”. The research report is titled “Emerging Cancer Vaccines Market research by Types (Non Genetic Vaccines, Genetic Vaccines), By Applications (Cancer Research Centers, Cancer Hospital, Clinics, Others), By Players/Companies Antigenics, Avax Technologies, GlaxoSmithKline, Merck, Moderna, Northwest Biotherapeutics”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Emerging Cancer Vaccines Market Research Report

By Type

Non Genetic Vaccines, Genetic Vaccines

By Application

Cancer Research Centers, Cancer Hospital, Clinics, Others

By Companies

Antigenics, Avax Technologies, GlaxoSmithKline, Merck, Moderna, Northwest Biotherapeutics

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

233

Number of Tables & Figures

164

Customization Available

Yes, the report can be customized as per your need.


Global Emerging Cancer Vaccines Industry Outlook


Global Emerging Cancer Vaccines Market Report Segments:

The global Emerging Cancer Vaccines market is segmented on the basis of:

Types

Non Genetic Vaccines, Genetic Vaccines

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Cancer Research Centers, Cancer Hospital, Clinics, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Antigenics
  2. Avax Technologies
  3. GlaxoSmithKline
  4. Merck
  5. Moderna
  6. Northwest Biotherapeutics

Global Emerging Cancer Vaccines Market Overview


Highlights of The Emerging Cancer Vaccines Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Non Genetic Vaccines
    2. Genetic Vaccines
  1. By Application:

    1. Cancer Research Centers
    2. Cancer Hospital
    3. Clinics
    4. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Emerging Cancer Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Emerging Cancer Vaccines Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Emerging cancer vaccines are vaccines that have not been widely used yet, but may be more effective than traditional cancer vaccines. Emerging cancer vaccines may help prevent or treat certain types of cancers.

Some of the key players operating in the emerging cancer vaccines market are Antigenics, Avax Technologies, GlaxoSmithKline, Merck, Moderna, Northwest Biotherapeutics.

The emerging cancer vaccines market is expected to register a CAGR of 8.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Emerging Cancer Vaccines Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Emerging Cancer Vaccines Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Emerging Cancer Vaccines Market - Supply Chain
   4.5. Global Emerging Cancer Vaccines Market Forecast
      4.5.1. Emerging Cancer Vaccines Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Emerging Cancer Vaccines Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Emerging Cancer Vaccines Market Absolute $ Opportunity

5. Global Emerging Cancer Vaccines Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Emerging Cancer Vaccines Market Size and Volume Forecast by Type
      5.3.1. Non Genetic Vaccines
      5.3.2. Genetic Vaccines
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Emerging Cancer Vaccines Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Emerging Cancer Vaccines Market Size and Volume Forecast by Application
      6.3.1. Cancer Research Centers
      6.3.2. Cancer Hospital
      6.3.3. Clinics
      6.3.4. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Emerging Cancer Vaccines Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Emerging Cancer Vaccines Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Emerging Cancer Vaccines Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Emerging Cancer Vaccines Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Emerging Cancer Vaccines Demand Share Forecast, 2019-2026

9. North America Emerging Cancer Vaccines Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Emerging Cancer Vaccines Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Emerging Cancer Vaccines Market Size and Volume Forecast by Application
      9.4.1. Cancer Research Centers
      9.4.2. Cancer Hospital
      9.4.3. Clinics
      9.4.4. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Emerging Cancer Vaccines Market Size and Volume Forecast by Type
      9.7.1. Non Genetic Vaccines
      9.7.2. Genetic Vaccines
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Emerging Cancer Vaccines Demand Share Forecast, 2019-2026

10. Latin America Emerging Cancer Vaccines Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Emerging Cancer Vaccines Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Emerging Cancer Vaccines Market Size and Volume Forecast by Application
      10.4.1. Cancer Research Centers
      10.4.2. Cancer Hospital
      10.4.3. Clinics
      10.4.4. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Emerging Cancer Vaccines Market Size and Volume Forecast by Type
      10.7.1. Non Genetic Vaccines
      10.7.2. Genetic Vaccines
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Emerging Cancer Vaccines Demand Share Forecast, 2019-2026

11. Europe Emerging Cancer Vaccines Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Emerging Cancer Vaccines Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Emerging Cancer Vaccines Market Size and Volume Forecast by Application
      11.4.1. Cancer Research Centers
      11.4.2. Cancer Hospital
      11.4.3. Clinics
      11.4.4. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Emerging Cancer Vaccines Market Size and Volume Forecast by Type
      11.7.1. Non Genetic Vaccines
      11.7.2. Genetic Vaccines
   11.8. Basis Point Share (BS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Emerging Cancer Vaccines Demand Share, 2019-2026

12. Asia Pacific Emerging Cancer Vaccines Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Emerging Cancer Vaccines Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Emerging Cancer Vaccines Market Size and Volume Forecast by Application
      12.4.1. Cancer Research Centers
      12.4.2. Cancer Hospital
      12.4.3. Clinics
      12.4.4. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Emerging Cancer Vaccines Market Size and Volume Forecast by Type
      12.7.1. Non Genetic Vaccines
      12.7.2. Genetic Vaccines
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Emerging Cancer Vaccines Demand Share, 2019-2026

13. Middle East & Africa Emerging Cancer Vaccines Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Emerging Cancer Vaccines Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Emerging Cancer Vaccines Market Size and Volume Forecast by Application
      13.4.1. Cancer Research Centers
      13.4.2. Cancer Hospital
      13.4.3. Clinics
      13.4.4. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Emerging Cancer Vaccines Market Size and Volume Forecast by Type
      13.7.1. Non Genetic Vaccines
      13.7.2. Genetic Vaccines
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Emerging Cancer Vaccines Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Emerging Cancer Vaccines Market: Market Share Analysis
   14.2. Emerging Cancer Vaccines Distributors and Customers
   14.3. Emerging Cancer Vaccines Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Antigenics
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Avax Technologies
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. GlaxoSmithKline
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Merck
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Moderna
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Northwest Biotherapeutics
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. COMPANY7
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. COMPANY8
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. COMPANY9
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us